The "KEY OF HOPE" program is aimed at increasing the awareness of patients about the disease and reducing the cost of therapy for the patient with drugs included in the Program, intended for the treatment of certain types of oncological diseases by influencing the immune system;
Preparation of the project:
KITRUDA® (pembrolizumab)
Keytruda conc. d/r-nu d/inf. 25 mg/ml fl. 4 ml No. 1
The promotion is held until: 31.12.2025
You can learn more about the terms of participation in the project on the website: https://medicard.com.ua/medicard/page/programms/
the company is focused on the key needs in healthcare, the development of new medicines, technologies and treatments. This is an international diversified company operating in the health sector. Time-tested products are highly appreciated by experts worldwide for its efficiency, reliability and safety. Program Time (ABBOTT CARDS ) provides the opportunity to purchase efficient medications at a more affordable price.
Drugs project:
Heptral since.lyophil.d/R-RA d/INF.500mg FL., No. The 5+solution.amp.5ml No. 5
Heptral tab.enteric solution.500 mg No. 20More details about conditions of participation in the project can be found on the project website Abbott cards
Darnitsa is a pharmaceutical company, a leader in Ukrainian market in the production and physical sales of prescription (Rx) and over-the-counter (OTC) generic products. The company began operating in 1930. In 2019, Darnitsa rebranded and announced a new business strategy: to transform based on digital technologies, to build an international brand and to lead in the generic segment of medicines.
The company's portfolio includes 280 names of ready-to-use drugs. Darnitsa focuses on the treatment of cardiac, neurological diseases and pain. Its products are exported to 16 countries.
The Darnitsa plant in Kyiv has 14 production lines certified according to the GMP standard.
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology, respiratory diseases.
Orion's main market is Finland, where it is the clear market leader. Orion’s products are marketed in over a hundred countries, and the Group's own human pharmaceuticals sales organization covers almost all key European markets and a few Southeast Asian countries. In other markets Orion’s products are sold by several collaboration partners. All of Orion's manufacturing plants and most of its R&D operations are in Finland. Orion’s headquarters are in Espoo.
“PLUS Therapy” – the program aims to support patients with chronic diseases in areas such as cardiology, endocrinology, pneumology, psychiatry and Oncology. For each Drug, which participates in the Program, define an appropriate charging scheme discounts. The discount is given to cardholders ‘Terapias”, which are issued to patients who had been prescribed the drug involved in the Program “Terapias”, by a doctor of the healthcare institution.
Drugs project:
Atacand table.16my No. 28
Atacand table.8mg No. 28
Brilinta table. p/o 90my No. 56
Combogia XR table.p/p/o of 2.5 mg/1000mg No. 28
Combogia XR table.n/a n/a 5mg/1000mg No. 28
Crestor tabl.n/a 10mg number 28
Crestor tabl.n/a 20 n 28
Crestor tabl.p/p/o 40mg No. 28
Crestor tabl.n/a 5 mg №28
Onglyza table.p/p/2.5 mg No. 30
Onglyza table.p/p/o 5 mg number 30
Symbicort Turbuhaler since.d/ing.160мкг/4.5 mcg/d. 60D
Symbicort Turbuhaler since.d/ing.320мкг/9.0 µg/d. 60D
Symbicort Turbuhaler since.d/ing.80мкг/4.5 mcg/d. 60D
FixYa table.p/p/about 10mg №30
Xiguo Prolong table.p/p/prolong.actions.10/1000mg No. 28
Xiguo Prolong table.p/p/prolong.actions.5/1000mg No. 28More details about conditions of participation in the project can be found on the project website Therapy PLUS
«Perrigo is a world leading health company which creates and provides non-prescription (ОТС) and perscription (Rx) medicines, consumer goods, food products and active pharmaceutical ingredients (API). Since 1887, Perrigo has been providing its customers and consumers with high-quality products that support personal health and wellness by delivering effective solutions that meet the needs of consumers almost all over the world – mostly in Northern America, Europe, Australia, and other key markets like Israel and China».
“the MAP of hope” – program to SUPPORT patients in areas such as gynecology and Oncology.
Drugs project:
Magrisso table.p/p/on 80 mg number 30
Limpeza caps.TV.50mg n448
Linparza tablets p / p / o 100mg No. 56
Linparza tablets p / p / o 150mg No. 56More details about conditions of participation in the project can be found on https://medicard.com.ua/medicard/page/programms/
the Program «For life” – this discount program which is organized by the company «Pfizer Export Bi.VI.”.
The aim of the Programme – make the drug company Pfizer participating in the Program and prescribed by the attending physician, more accessible to all patients.Drugs project:
Sutent caps.12.5 mg # 28
Sutent caps.25mg no 28
Sutent caps.50mg no 28
Ibras caps.100mg №21
Ibras caps.125мг No. 21
Ibras caps.75mg №21
Calcari caps.200mg blister No. 60
Calcari caps.250mg no 60
Inlet table.p/p/about 1 mg №56
Inlet table.p/p/o 5 mg №56
Maylotarg 4.5 mg No
Talzenna 1 mg No. 30
Talzenna 0,25 mg No. 30
More details about conditions of participation in the project can be found on :http://www.pfizermed.com.ua/public/zarady-zhittya
the Company RECORDED GROUPS, with headquarters in Milan (Italy), has offices in many countries of Central and Eastern Europe, in Russia, in Turkey, in North Africa and in the United States of America.
The program “Let’s Keep Healthy Together” is aimed at supporting patients with chronic diseases related to such branches as: gynecology, urology, surgery, therapy, oncology and others.
The main goal of the program “Let’s Keep Healthy Together” is to increase patient adherence to prescribed therapy by:Drugs project:
• raising awareness of patients about the disease;
• reducing the cost of therapy.You can learn more about the conditions of participation in the project at: https://medicard.com.ua
